Trial · NCT03611751
Adverse events288
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 288
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | BMS-986165 (Week 0 up to Week 16) | 24 | 510 | |
| other | Diarrhoea | Gastrointestinal disorders | Placebo (Week 0 up to Week 16) | 19 | 254 | |
| other | Diarrhoea | Gastrointestinal disorders | Apremilast (Week 0 up to Week 16) | 33 | 254 | |
| other | Diarrhoea | Gastrointestinal disorders | BMS-986165 (Week 0 up to Week 52) | 39 | 833 | |
| other | Diarrhoea | Gastrointestinal disorders | Placebo (Week 0 up to Week 52) | 22 | 501 | |
| other | Diarrhoea | Gastrointestinal disorders | Apremilast (Week 0 up to Week 52) | 35 | 254 | |
| other | Nausea | Gastrointestinal disorders | BMS-986165 (Week 0 up to Week 16) | 7 | 510 | |
| other | Nausea | Gastrointestinal disorders | Placebo (Week 0 up to Week 16) | 3 | 254 | |
| other | Nausea | Gastrointestinal disorders | Apremilast (Week 0 up to Week 16) | 23 | 254 | |
| other | Nausea | Gastrointestinal disorders | BMS-986165 (Week 0 up to Week 52) | 13 | 833 | |
| other | Nausea | Gastrointestinal disorders | Placebo (Week 0 up to Week 52) | 6 | 501 | |
| other | Nausea | Gastrointestinal disorders | Apremilast (Week 0 up to Week 52) | 26 | 254 | |
| other | Nasopharyngitis | Infections and infestations | BMS-986165 (Week 0 up to Week 16) | 55 | 510 | |
| other | Nasopharyngitis | Infections and infestations | Placebo (Week 0 up to Week 16) | 29 | 254 | |
| other | Nasopharyngitis | Infections and infestations | Apremilast (Week 0 up to Week 16) | 23 | 254 | |
| other | Nasopharyngitis | Infections and infestations | BMS-986165 (Week 0 up to Week 52) | 133 | 833 | |
| other | Nasopharyngitis | Infections and infestations | Placebo (Week 0 up to Week 52) | 47 | 501 | |
| other | Nasopharyngitis | Infections and infestations | Apremilast (Week 0 up to Week 52) | 28 | 254 | |
| other | Upper respiratory tract infection | Infections and infestations | BMS-986165 (Week 0 up to Week 16) | 25 | 510 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo (Week 0 up to Week 16) | 11 | 254 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03611751/events